49
3
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T4266 | LY334370 | LY 334370 | 5-HT Receptor |
LY334370 is a selective 5-HT1F receptor agonist with a Ki of 1.6 nM | |||
T7810 | LY3177833 | LY-3177833 | CDK |
LY3177833 is an Cdc7 kinase inhibitor (IC50 : 3.3 nM) | |||
T5125 | LY3200882 | TGF-beta/Smad | |
LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). | |||
T9064 | LY3143921 hydrate | CDK | |
LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1]. | |||
T15816 | LY341495 | GluR | |
LY341495 is a potent metabotropic glutamate receptor antagonist that exhibits high activity against a wide range of glutamate receptor subtypes and can be used for the study of neurological disorders. | |||
T61661 | LY3372689 | Formulaic Ia | Microtubule Associated |
LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor for tau protein-based disorders including Alzheimer's disease. | |||
T15815 | LY3295668 | AK-01 | Aurora Kinase |
LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively. | |||
T6882 | LY3009120 | DP-4978 | Raf , Autophagy |
LY3009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1. | |||
T15819 | LY377604 | Adrenergic Receptor | |
LY377604 is a human β3-adrenergic receptor agonist (EC50: 2.4 nM) and β1/2-adrenergic receptor antagonist for the study of obesity. | |||
T9078 | LY3405105 | 1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester | CDK |
LY3405105 (1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester) is a novel CDK7 inhibitors. | |||
T27949 | LY382884 | LY-382884,LY 382884 | GluR |
LY382884 is a selective and potent GluR5 kainate receptor antagonist with anxiolytic activity.LY382884 blocks blockade of mossy fibre LTP induction. | |||
T27951 | LY392098 | LY-392098,LY 392098,AMPA receptor modulator-3 | GluR , iGluR |
LY392098 (AMPA receptor modulator-3) is an allosteric modulator of AMPA receptor with EC50 of 4.4 μM and can be used in studies about mammalian nervous system. | |||
T27947L | LY339434 HCl | LY339434 HCl(219566-62-8 Free base) | GluR , NMDAR |
LY339434 HCl is a low affinity GluR5 erythrocyte receptor agonist.LY339434 HCl causes rapid neuronal death primarily by affecting N-methyl-D-aspartate (NMDA) receptors. | |||
T2688 | LY310762 | LY310762 HCl | 5-HT Receptor |
LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM. | |||
T78626 | LY393615 | NCC1048 | Calcium Channel |
LY393615 (NCC1048) is a novel blocker of both neuronal Ca²⁺ (calcium) and Na⁺ (sodium) channels, exhibiting half-maximal inhibitory concentrations (IC₅₀) of 1.9 µM and 5.2 µM against α1A and α1B calcium channel subunits,... | |||
T27942 | LY307452 | LY 307452,LY-307452 | |
LY307452 is a selective antagonist of mGluR2/3. | |||
T11912 | LY3154207 | Others | |
LY3154207 is a subtype selective, potent, and orally available human dopamine D1 receptor positive allosteric modulator (PAM) with minimal allosteric agonist activity (EC50=3 nM). | |||
T18246 | Mal-C2-Gly3-EDA-PNU-159682 | Others | |
Mal-C2-Gly3-EDA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), combines the cleavable ADC linker Mal-C2-Gly3-EDA with the potent ADC cytotoxin PNU-159682. | |||
T27945 | LY320954 | LY 320954,PDSP1_001629,LY-320954 | |
LY320954 is an antagonist of 5-HT2A receptor. | |||
T27940 | LY301875 | LY 301875,LY-301875 | |
LY301875 is an antagonist of nonpeptide angiotensin receptor. | |||
T11911 | LY3020371 hydrochloride | GluR | |
LY3020371 hydrochloride exerts an antidepressant-like signature in vivo. LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, potently blocks ... | |||
T77828 | Fmoc-Gly3-Val-Cit-PAB | ||
Fmoc-Gly3-Val-Cit-PAB is a cleavable linker utilized in the assembly of antibody-drug conjugates (ADCs). | |||
T60747 | LY3143921 | ||
LY3143921 ((S)-Example 2) is an orally active inhibitor of CDC7 kinase with broad in vitro anticancer activity [1]. | |||
T82384 | Fmoc-Gly3-VC-PAB-MMAE | ||
Fmoc-Gly3-VC-PAB-MMAE is a drug-linker conjugate utilized in antibody-drug conjugates (ADCs), composed of the potent cytotoxic agent Monomethyl auristatin E (MMAE) tethered via a cleavable linker [1]. | |||
T27943 | LY314228 | LY-314228,LY 314228 | |
LY314228 is an antagonist of 5-HT2A receptor. | |||
T62610 | LY3154885 | ||
LY3154885 is an orally active dopamine D1 receptor orthosteric modulator (PAM) that reduces the risk of drug-drug interactions (DDI). | |||
T38792 | LY3027788 | LY3027788 | |
LY3027788, a diester analog of LY3020371, an mGlu2/3 receptor antagonist, is a highly potent and orally active prodrug of LY3020371. Notably, LY3027788 exhibits significant antidepressant efficacy. | |||
T15813 | LY309887 | LTR | |
LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (Ki: 6.5 nM). It also has antitumor activity. | |||
T15814 | LY3130481 | Others | |
LY3130481 is an AMPA receptor antagonist. It is dependent upon transmembrane AMPA receptor regulatory protein (TARP) γ-8 and selectively inhibits AMPA/TARP γ-8 (IC50: 65 nM). | |||
T15818 | LY367385 | FXR | |
LY367385 is a highly effective and selective mGluR1a antagonist. LY367385 has neuroprotective, anticonvulsant, and antiepileptic effects. Compared with > 100 μM for mGlu5a, LY367385 has an IC50 of 8.8 μM for inhibits of ... | |||
T27941 | LY303336 | LY-303336,LY 303336 | |
LY303336 is an antagonist of AT1 receptor. | |||
T24422 | LY3104607 | LY 3104607,LY-3104607 | |
LY3104607 is a G Protein-Coupled Receptor 40 agonist. It is active in oral treatment for patients with type 2 diabetes mellitus and is a glucose-lowering drug candidate. | |||
T60355 | LY367385 hydrochloride | ||
LY367385 hydrochloride is a potent and selective mGluR1a antagonist with an IC50 value of 8.8 μM for inhibiting quisqualate-induced phosphoinositide (PI) hydrolysis, showing significantly higher selectivity compared to i... | |||
T33013 | LY334362 | LY 334362,LY-334362 | |
LY334362 is a bioactive chemical. | |||
T27947 | LY339434 | LY 339434,LY-339434 | |
LY339434 is a potent and selective agonist of the kainate receptor GluK1, GluR5. | |||
T22951 | LY320135 | LY 320135 | Others |
CB1 receptor antagonist/inverse agonist | |||
T39406 | (±)-LY367385 | (±)-LY367385 | |
(±)-LY367385 is the racemic form of LY367385, and LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 exhibits a high inhibitory activity against quisqualate-induced phosphoinositide (PI) hydrolysis, w... | |||
T72384 | (S)-LY3177833 hydrate | ||
(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy. | |||
T70005 | LY3325656 | ||
LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR1... | |||
T38791 | LY3020371 | ||
LY3020371 is a highly potent and selective antagonist targeting the glutamate (mGlu) 2/3 receptor, showcasing excellent inhibition at Ki values of 5.26 nM and 2.50 nM for hmGluR2 and hmGluR3, respectively. With its remar... | |||
T38790 | LY3027788 hydrochloride | ||
LY3027788 hydrochloride is a diester analog of LY3020371, a selective antagonist of the metabotropic glutamate 2 and 3 receptors (mGlu2/3). It serves as a highly potent and orally bioavailable prodrug of LY3020371. Notab... | |||
T27944 | LY3202626 | LY 3202626,LY-3202626 | |
LY3202626, an amyloid precursor protein secretase (BACE protein) inhibitor, is used for the treatment of Alzheimer's disease. | |||
T27950 | LY389795 | LY-389795,LY 389795 | |
LY389795 is an agonist of group II (mGlu2/3) metabotropic glutamate receptor, it is used in inflammatory pain models. | |||
T61610 | NPEC-caged-LY379268 | ||
NPEC-caged-LY379268 is a type II mGluR agonist [1]. | |||
T18247 | Mal-C2-Gly3-EDA | Others | |
Mal-C2-Gly3-EDA is a cleavable antibody-drug conjugate (ADC) linker equipped with a Maleimide moiety. It serves the purpose of facilitating the synthesis of ADCs. | |||
T40308 | Gly3-VC-PAB-MMAE | Gly3-VC-PAB-MMAE | |
Gly3-VC-PAB-MMAE is a chemical compound comprised of a cleavable antibody-drug conjugate (ADC) linker, Gly3-VC-PAB, and a potent inhibitor of tubulin, MMAE. It is utilized in the synthesis of ADCs. | |||
T63053 | MALT1-IN-3 | ||
MALT1-IN-3 is a potent inhibitor of MALT1 protease (IC50: 0.06 μM) with IC50 values of 0.14 and 0.13 μM for human IL6 and IL10, respectively, in OCI-LY3 cells. | |||
T62533 | MALT1-IN-8 | ||
MALT1-IN-8 is a potent inhibitor of MALT1 protease (IC50: 2 nM). MALT1-IN-8 inhibits the growth of OCI-LY3 lymphoma cells (IC50: 1.16 μM) and exhibits anticancer activity. | |||
T63051 | (R)-MALT1-IN-3 | ||
(R)-MALT1-IN-3 (compound 121) is a potent inhibitor of MALT1 protease (IC50: 20 nM) with IC50 values of 60 nM and 40 nM for human IL6/IL10 in OCI-LY3 cells, respectively. |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04925 | CD8 beta Protein, Human, Recombinant, Biotinylated | Human | HEK293 Cells |
CD8 beta Protein, Human, Recombinant, Biotinylated is expressed in HEK293 mammalian cells. The predicted molecular weight is 17.6 kDa and the accession number is P10966-1. | |||
TMPY-02925 | CD8 beta Protein, Human, Recombinant | Human | HEK293 Cells |
CD8 beta Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 17.6 kDa and the accession number is P10966-1. | |||
TMPY-02703 | CD8 beta Protein, Human, Recombinant (hFc) | Human | HEK293 Cells |
CD8 beta Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44 kDa and the accession number is P10966-1. |